Development of Pharmaceutical Nanomedicines: From the Bench to the Market
Nanotechnology plays a significant role in the field of medicine and in drug delivery, mainly due to the major limitations affecting the conventional pharmaceutical agents, and older formulations and delivery systems. The effect of nanotechnology on healthcare is already being felt, as various nanot...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/1/106 |
| _version_ | 1797491150478639104 |
|---|---|
| author | Abdulrahman A. Halwani |
| author_facet | Abdulrahman A. Halwani |
| author_sort | Abdulrahman A. Halwani |
| collection | DOAJ |
| description | Nanotechnology plays a significant role in the field of medicine and in drug delivery, mainly due to the major limitations affecting the conventional pharmaceutical agents, and older formulations and delivery systems. The effect of nanotechnology on healthcare is already being felt, as various nanotechnology applications have been developed, and several nanotechnology-based medicines are now on the market. Across many parts of the world, nanotechnology draws increasing investment from public authorities and the private sector. Most conventional drug-delivery systems (CDDSs) have an immediate, high drug release after administration, leading to increased administration frequency. Thus, many studies have been carried out worldwide focusing on the development of pharmaceutical nanomedicines for translation into products manufactured by local pharmaceutical companies. Pharmaceutical nanomedicine products are projected to play a major role in the global pharmaceutical market and healthcare system. Our objectives were to examine the nanomedicines approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the global market, to briefly cover the challenges faced during their development, and to look at future perspectives. Additionally, the importance of nanotechnology in developing pharmaceutical products, the ideal properties of nanocarriers, the reasons behind the failure of some nanomedicines, and the important considerations in the development of nanomedicines will be discussed in brief. |
| first_indexed | 2024-03-10T00:43:19Z |
| format | Article |
| id | doaj.art-9c09b8068f804296a13e2533ee15f482 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T00:43:19Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-9c09b8068f804296a13e2533ee15f4822023-11-23T15:03:59ZengMDPI AGPharmaceutics1999-49232022-01-0114110610.3390/pharmaceutics14010106Development of Pharmaceutical Nanomedicines: From the Bench to the MarketAbdulrahman A. Halwani0Pharmaceutics Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah 22252, Saudi ArabiaNanotechnology plays a significant role in the field of medicine and in drug delivery, mainly due to the major limitations affecting the conventional pharmaceutical agents, and older formulations and delivery systems. The effect of nanotechnology on healthcare is already being felt, as various nanotechnology applications have been developed, and several nanotechnology-based medicines are now on the market. Across many parts of the world, nanotechnology draws increasing investment from public authorities and the private sector. Most conventional drug-delivery systems (CDDSs) have an immediate, high drug release after administration, leading to increased administration frequency. Thus, many studies have been carried out worldwide focusing on the development of pharmaceutical nanomedicines for translation into products manufactured by local pharmaceutical companies. Pharmaceutical nanomedicine products are projected to play a major role in the global pharmaceutical market and healthcare system. Our objectives were to examine the nanomedicines approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the global market, to briefly cover the challenges faced during their development, and to look at future perspectives. Additionally, the importance of nanotechnology in developing pharmaceutical products, the ideal properties of nanocarriers, the reasons behind the failure of some nanomedicines, and the important considerations in the development of nanomedicines will be discussed in brief.https://www.mdpi.com/1999-4923/14/1/106nanotechnologypharmaceutical nanomedicinesnanoparticlesdrug delivery |
| spellingShingle | Abdulrahman A. Halwani Development of Pharmaceutical Nanomedicines: From the Bench to the Market Pharmaceutics nanotechnology pharmaceutical nanomedicines nanoparticles drug delivery |
| title | Development of Pharmaceutical Nanomedicines: From the Bench to the Market |
| title_full | Development of Pharmaceutical Nanomedicines: From the Bench to the Market |
| title_fullStr | Development of Pharmaceutical Nanomedicines: From the Bench to the Market |
| title_full_unstemmed | Development of Pharmaceutical Nanomedicines: From the Bench to the Market |
| title_short | Development of Pharmaceutical Nanomedicines: From the Bench to the Market |
| title_sort | development of pharmaceutical nanomedicines from the bench to the market |
| topic | nanotechnology pharmaceutical nanomedicines nanoparticles drug delivery |
| url | https://www.mdpi.com/1999-4923/14/1/106 |
| work_keys_str_mv | AT abdulrahmanahalwani developmentofpharmaceuticalnanomedicinesfromthebenchtothemarket |